Patents Assigned to Merck
  • Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
    Patent number: 12281109
    Abstract: The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing cancer, inflammation, neurodegeneration disease and/or diabetes in a subject.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 22, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Jian Liu, Younong Yu, Joseph A. Kozlowski, Deyou Sha, Wensheng Yu, Joseph M. Kelly, Scott E. Wolkenberg
  • Pneumococcal conjugate vaccine formulations
    Patent number: 12280107
    Abstract: The present invention provides pneumococcal conjugate vaccine formulations comprising surfactant systems incorporating polysorbate 20 or a combination of a poloxamer and a polyol.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: April 22, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: William J. Smith, Cecilia Giovarelli, Denise K. Nawrocki
  • ANTI-CEACAM5 ANTIBODIES AND CONJUGATES AND USES THEREOF
    Publication number: 20250122282
    Abstract: Antibodies which bind human CEACAM5 protein, as well as isolated nucleic acids and host cells containing a sequence encoding said antibodies are disclosed. Immunoconjugates containing said antibodies linked to a growth-inhibitory agent, and pharmaceutical compositions containing antibodies or said immunoconjugates are also disclosed. A use of the antibodies, immunoconjugates, and pharmaceutical compositions disclosed herein is provided for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: August 13, 2021
    Publication date: April 17, 2025
    Applicant: Merck Patent GmbH
    Inventors: Jan Anderl, Sabine Raab-Westphal, Stefan Hecht, Carl Deutsch, Min Shan, Doreen Könning, Willem N. Sloot, Felix Hart, Christian Schröter, Lars Toleikis, Nir Berger
  • Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 12275729
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: April 15, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongqi Deng, Abdelghani Achab, David Jonathan Bennett, Indu Bharathan, Xavier Fradera, Craig Gibeau, Yongxin Han, Derun Li, Kun Liu, Qinglin Pu, Sulagna Sanyal, David Sloman, Wensheng Yu, Hongjun Zhang
  • Materials for electronic devices
    Patent number: 12275682
    Abstract: The present application relates to materials for use in electronic devices, to processes for preparing the materials, and to electronic devices containing the materials.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: April 15, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Elvira Montenegro, Teresa Mujica-Fernaud, Florian Maier-Flaig, Frank Voges
  • Materials for organic electroluminescent devices
    Patent number: 12279521
    Abstract: The invention relates to fluorene derivatives and electronic devices, particularly organic electroluminescent devices in which said compounds are used, particularly as a matrix material for phosphorescent emitters.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: April 15, 2025
    Assignee: Merck Patent GmbH
    Inventors: Nils Koenen, Anna Hayer, Florian Maier-Flaig, Jochen Pfister, Holger Heil
  • Anti-coagulation factor XI antibodies
    Patent number: 12275800
    Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: April 15, 2025
    Assignees: Merck Sharp & Dohme LLC, Adimab, LLC
    Inventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
  • Novolak/DNQ based, chemically amplified photoresist
    Patent number: 12276909
    Abstract: The present invention relates to resist compositions comprising a polymer component, a photoacid generator component (PAG), a photoactive diazonaphthoquinone component (PAC), a base component, a solvent component, and optionally, a heterocyclic thiol component. The polymer component is a Novolak derivative, comprising Novolak repeat units with free phenolic hydroxy moieties, and Novolak repeat units comprising phenolic hydroxy moieties protected with an acid cleavable acetal moiety.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: April 15, 2025
    Assignee: Merck Patent GmbH
    Inventors: Medhat A. Toukhy, Weihong Liu, Takanori Kudo, Hung-Yang Chen, Jian Yin
  • THERAGNOSTIC FOLATE CONJUGATES
    Publication number: 20250108138
    Abstract: The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydrofolate, a radiometal chelator optionally coordinating a radiometal M, and an albumin binder linked through a hydrophobic linker, and further provides uses of such conjugates and/or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy or theragnostic applications.
    Type: Application
    Filed: January 30, 2023
    Publication date: April 3, 2025
    Applicant: MERCK PATENT GMBH
    Inventors: Viola GROEHN, Marie-Luise RENZ, Rudolf MOSER, Roger SCHIBLI, Cristina Magdalena MUELLER, Martina BENESOVA, Patrycja GUZIK, Luisa Maria DEBERLE, Anna Elisabeth BECKER, Sara Dorina BUSSLINGER
  • 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
    Patent number: 12263171
    Abstract: In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: April 1, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yonglian Zhang, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Thomas H. Graham, Elisabeth Hennessy, Matthew A. Larsen, Kun Liu, Ping Liu, Umar Faruk Mansoor, Jianping Pan, Christopher W. Plummer, Aaron Sather, Uma Swaminathan, Huijun Wang
  • Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
    Patent number: 12264134
    Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 1, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
  • Aryl sulfonamides as BLT1 antagonists
    Patent number: 12264139
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: April 1, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Yongxin Han, Jongwon Lim, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
  • Liquid-crystal medium comprising polymerizable compounds
    Patent number: 12264276
    Abstract: The present invention relates to an LC medium comprising two or more polymerizable compounds, at least one of which contains a substituent comprising a tertiary OH group, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (polymer sustained alignment) or SA (self-aligning) mode, to an LC display of the PSA or SA mode comprising the LC medium, and to a process of manufacturing the LC display using the LC medium, especially an energy-saving LC display and energy-saving LC display production process.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: April 1, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Min Tzu Chuang, I-Wen Chen, Cheng-Jui Lin, Jer-Lin Chen, Kuang-Ting Chou
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20250099478
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: January 23, 2023
    Publication date: March 27, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Anthony K. Ogawa, Christopher J. Sinz, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Rohan Rajiv Merchant, Natalija Cernaka, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang, Maoqun Tian, Mihir B. Mandal, Jiafang He
  • METHODS FOR TREATING ACUTE MYELOID LEUKEMIA WITH ANTI-ILT3 ANTIBODIES
    Publication number: 20250101097
    Abstract: This disclosure relates to methods for treating cancer in a subject identified as having acute myeloid leukemia (AML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).
    Type: Application
    Filed: July 25, 2022
    Publication date: March 27, 2025
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cai Wu, Daping Zhang, Jie Zhang-Hoover
  • Liquid crystal medium
    Patent number: 12258510
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising a compound of formula I and one or more compounds selected from the group of compounds of the formulae IIA, IIB, IIC and IID, as defined in claim 1, and to the use thereof for optical, electro-optical and electronic purposes, in particular in LC displays, especially in IPS, FFS, VA or PS-VA displays.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: March 25, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Sven Christian Laut, Fisher (Shuo) Yu
  • Pyrimidone derivatives as selective cytotoxic agents against HIV infected cells
    Patent number: 12258329
    Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: March 25, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Antonella Converso, Cheng Wang
  • Optical component
    Patent number: 12258509
    Abstract: An optical component is described which contains a liquid crystal (LC) medium, operable in the infrared region of the electromagnetic spectrum. The LC medium, which can be used in the infrared (IR) region, can contain one or more compounds of the formulae I, II, and III in which the occurring groups and parameters have the meanings defined herein, and preferably contain one or more compounds of the formula RO in which the occurring groups and parameters have the meanings defined herein.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: March 25, 2025
    Assignee: MERCK PATENT GMBH
    Inventors: Izumi Saito, Owain Llyr Parri, Andreas Taugerbeck, Carsten Fritzsch, Dagmar Klass
  • COMPOSITIONS INCLUDING SOLID FORMS OF POLYPEPTIDES AND RELATED METHODS
    Publication number: 20250092138
    Abstract: Compositions including solid forms of polypeptides such as crystalline antibodies, and related methods, are generally described. The compositions may include carriers such as hydrogels that at least partially encapsulate the solid form of the polypeptides (e.g., crystals, amorphous solids). Encapsulation with certain of the materials described may result in compositions containing relatively high loadings of polypeptides while in some instances retaining structural and functional properties of the polypeptides useful for certain types of administration to subjects (e.g., for prophylactic or therapeutic applications). In some instances, compositions having relatively low dynamic viscosities while having relatively high polypeptide loadings are provided.
    Type: Application
    Filed: July 30, 2021
    Publication date: March 20, 2025
    Applicants: Massachusetts Institute of Technology, Merck Sharp & Dohme Corp
    Inventors: Patrick S. Doyle, Jeremy Schieferstein, Paul Reichert, Chakravarthy Narasimhan, Amir Erfani-Khaneghahi
  • Substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
    Patent number: 12251382
    Abstract: Methods, compositions, and medical kits are useful for treating and preventing multiple sclerosis using 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, or a pharmaceutically acceptable salt thereof, according to preferred dosing regimens.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: March 18, 2025
    Assignee: Merck Patent GmbH
    Inventors: Martin Dyroff, David Mitchell, Orestis Papasouliotis